Are SPACs Better Than Traditional IPOs?
Outcome Capital’s Managing Director Paul Mieyal, Ph.D., CFA was interviewed by BioSpace for his views on the recent popularity of SPACs in the biotech space. The interview covers historical perspective, current market dynamics, and outlook for the next year.
Published: Mar 10, 2021 By Kate Goodwin
Outcome Capital’s Managing Director Paul Mieyal, Ph.D., CFA was interviewed by BioSpace for his views on the recent popularity of SPACs in the biotech space. The interview covers historical perspective, current market dynamics, and outlook for the next year.
News
Outcome Capital Continues to Expand with the Addition of Charles Simmons
Appointment of Charles Simmons as Managing Director continues to strengthen Outcome’s capabilities
Read MoreResources
Outcome Capital Life Science Market Pulse, November 2024
Outcome Capital Life Science Market Pulse November 2024 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2024. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy | Regulation Best Interest
